Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.41 |
| ▸ | HTR3B | O95264 | 4/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881195 | 1.00 | HTR3A (0.49) | HTR3AMEN1KMT2AHTR4HTR2A | |
| SCHEMBL7276342 | 0.82 | HTR3A (0.50) | HTR3AMEN1KMT2AHTR4HTR3E | |
| Hydrochloric Acid SCHEMBL7281701 | 0.82 | HTR3A (0.49) | HTR3AMEN1KMT2AHTR4HTR2A | |
| SCHEMBL7287907 | 0.82 | HTR3E (0.57) | HTR3AMEN1KMT2ACYP1A2HTR3E | |
| Hydrochloric Acid SCHEMBL7279269 | 0.80 | HTR3A (0.48) | HTR3AMEN1KMT2AHTR4HTR3E | |
| SCHEMBL7270890 | 0.79 | HTR3A (0.48) | HTR3AMEN1KMT2AHTR4KCNH2 | |
| SCHEMBL7281537 | 0.78 | SLC6A12 (0.56) | HTR3AHTR2APDE4DKCNH2CYP1A2 | |
| SCHEMBL7281427 | 0.78 | HTR3A (0.52) | HTR3AMEN1KMT2ACYP1A2HTR3E | |
| SCHEMBL7281271 | 0.78 | HTR3A (0.71) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL8940024 | 0.78 | HTR3A (0.52) | HTR3AMEN1KMT2AHTR4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0313393-B1 | Benzoxazine compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1994-03-16 | — | — | EP | claimed |
| US-4892872-A | ANTIEMETICS, ANTINAUSEA | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | claimed |
| EP-0313393-A2 | Benzoxazine compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | claimed |
| US-20250170139-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2025-05-29 | — | — | US | disclosed |
| EP-4335508-A2 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | Sensorion (FR) | 2024-03-13 | — | — | EP | disclosed |
| EP-3442537-B1 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | SENSORION (FR) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023175078-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2023-09-21 | — | — | WO | disclosed |
| US-20230226071-A1 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | SENSORION (FR) | 2023-07-20 | — | — | US | disclosed |
| US-11612605-B2 | (+)-azasetron for use in the treatment of ear disorders | SENSORION (FR) | 2023-03-28 | — | — | US | disclosed |
| US-20220387438-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2022-12-08 | — | — | US | disclosed |
| US-11433077-B2 | Calcineurin inhibitors of the setron family for the treatment of hearing loss | SENSORION (FR) | 2022-09-06 | — | — | US | disclosed |
| EP-3909579-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | Sensorion (FR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3297628-B1 | AZASETRON FOR USE IN THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021014014-A1 | TREATMENT AND/OR PREVENTION OF LESIONS IN THE CENTRAL AUDITORY NERVOUS SYSTEM | SENSORION (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-20190083503-A1 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | SENSORION (FR) | 2019-03-21 | — | — | US | disclosed |
| US-20180207167-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2018-07-26 | — | — | US | disclosed |
| EP-3297628-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | Sensorion (FR) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184900-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2016-11-24 | — | — | WO | disclosed |
| EP-0313393-B1 | Benzoxazine compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0313393-A2 | Benzoxazine compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612605-B2 | (+)-azasetron for use in the treatment of ear disorders | SLC26A4, OTC, ENTPD5 | HTR3A 788/4885MEN1 562/4885KMT2A 2437/4885 |
| US-20190083503-A1 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | SLC26A4, OTC, ENTPD5 | HTR3A 788/4885MEN1 562/4885KMT2A 2437/4885 |
| US-20180207167-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | CHP1, SENP7, SENP1 | HTR3A 4099/4885MEN1 591/4885KMT2A 1676/4885 |
| US-11433077-B2 | Calcineurin inhibitors of the setron family for the treatment of hearing loss | CHP1, SENP7, SENP1 | HTR3A 4099/4885MEN1 591/4885KMT2A 1676/4885 |
| US-20250170139-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | AASDHPPT, SCN3A, DNPEP | HTR3A 117/4885MEN1 1148/4885KMT2A 815/4885 |
| US-20230226071-A1 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | SLC26A4, SLC26A3, ENTPD5 | HTR3A 1344/4885MEN1 494/4885KMT2A 2646/4885 |
| US-20220387438-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | CHP1, SENP7, SENP1 | HTR3A 4099/4885MEN1 591/4885KMT2A 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.